Published in Br J Cancer on July 01, 1985
Tumour markers in germ cell tumours. Br Med J (Clin Res Ed) (1986) 0.75
Cancer survival in Britain is poorer than that of her comparable European neighbours. BMJ (1999) 4.39
New guidelines for urgent referral of patients with cancer are waste of energy. BMJ (2000) 2.66
Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet (1991) 2.26
Gene therapy for cancer. Lancet (1992) 1.81
Use of community genetic screening to prevent HFE-associated hereditary haemochromatosis. Lancet (2005) 1.68
c-myc oncogene expression in colorectal cancer. Cancer (1987) 1.60
A new indicator of human malignant tumour. Br J Cancer (1984) 1.60
Detection of the c-myc oncogene product in colonic polyps and carcinomas. Br J Cancer (1986) 1.47
Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. N Engl J Med (1978) 1.44
Detection of the c-myc oncogene product in testicular cancer. Br J Cancer (1985) 1.40
Amplification of natural regulatory immune mechanisms for transplantation tolerance. Transplantation (1996) 1.39
Centralize cancer services. Br J Hosp Med (1990) 1.38
Neurological effects of recombinant human interferon. Br Med J (Clin Res Ed) (1983) 1.37
Does interferon cure cancer? Br Med J (1980) 1.34
Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: a rapid and noninvasive dynamic method. Cancer Res (1992) 1.33
Stimulation of lymphocytes from patients with coeliac disease by a subfraction of gluten. Lancet (1976) 1.31
The increasing incidence of testicular cancer in East Anglia. Br J Cancer (1984) 1.28
Human hybridomas from malignant gliomas. Lancet (1982) 1.27
Second opinions for patients with cancer. BMJ (1995) 1.23
A simultaneous flow cytometric assay for c-myc oncoprotein and DNA in nuclei from paraffin embedded material. J Immunol Methods (1985) 1.21
Monoclonal antibodies that define canine homologues of human CD antigens: summary of the First International Canine Leukocyte Antigen Workshop (CLAW). Tissue Antigens (1994) 1.17
Cyclosporine does not prevent cytoplasmic calcium changes associated with lymphocyte activation. Transplantation (1984) 1.16
Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression. J Clin Oncol (1999) 1.13
A novel tumour marker related to the c-myc oncogene product. Mol Cell Probes (1987) 1.11
Interventional genetics and cancer treatment. BMJ (1993) 1.10
Human monoclonal antibodies to lung-cancer antigens. Br J Cancer (1981) 1.10
Oncogenes. Lancet (1983) 1.09
Monoclonal antibody which agglutinates erythrocytes from cancer patients. Lancet (1982) 1.07
Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile. Eur Neuropsychopharmacol (2001) 1.06
c-myc oncogene product expression and prognosis in operable breast cancer. Br J Cancer (1989) 1.06
Partial purification of tumour-specific transplantation antigens from methylcholanthrene-induced murine sarcomas by immobilized lectins. Br J Cancer (1979) 1.06
The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumour receptors. Br J Cancer (1990) 1.05
Gene therapy for cancer using tumour-specific prodrug activation. Gene Ther (1994) 1.04
Chromosomes and human pregnancy wastage. Am J Obstet Gynecol (1966) 1.02
The clinical significance of flow cytometric c-myc oncoprotein quantitation in testicular cancer. Br J Cancer (1986) 1.01
Coupling PPD to tumour cells enhances their antigenicity in BCG-primed mice. Nature (1978) 1.00
Value of follow up in testicular cancer. Br Med J (Clin Res Ed) (1984) 1.00
The heterogenization of tumour cells with tuberculin. II. Studies of the antigenicity of tuberculin-heterogenized murine tumour cells in syngeneic BCG positive and BCG negative mice. Immunology (1981) 1.00
Oncogene expression in cholangiocarcinoma and in normal hepatic development. Hum Pathol (1989) 0.99
Monoclonal immunoglobulin rescue from a patient with chronic lymphocytic leukemia and autoimmune hemolytic anemia. Blood (1979) 0.98
Localisation of metastatic carcinoma by a radiolabelled monoclonal antibody. Br J Cancer (1983) 0.98
Tumour inoculation during laparoscopy. Lancet (1993) 0.98
Conventional and complementary treatment for cancer. BMJ (1989) 0.97
Simple method of monitoring colonising microbial load in chronic bronchial sepsis: pilot comparison of reduction in colonising microbial load with antibiotics given intermittently and continuously. J Clin Pathol (1987) 0.96
Mouse-human hybridomas. The conversion of non-secreting human B cells into Ig secretors. Curr Top Microbiol Immunol (1978) 0.95
Tolerance in the mouse to major histocompatibility complex-mismatched heart allografts, and to rat heart xenografts, using monoclonal antibodies to CD4 and CD8. Eur J Immunol (1992) 0.94
Age as a prognostic factor in epithelial ovarian carcinoma. Br J Obstet Gynaecol (1985) 0.93
Recombinant interferon in advanced breast cancer. Br J Cancer (1984) 0.91
Mutational biosynthesis of novel rapamycins by a strain of Streptomyces hygroscopicus NRRL 5491 disrupted in rapL, encoding a putative lysine cyclodeaminase. J Bacteriol (1998) 0.91
Interferon and cancer. Br Med J (Clin Res Ed) (1983) 0.90
The heterogenization of tumour cells with tuberculin. I. The coupling of tuberculin to cell surfaces using con-A as ligand. Immunology (1981) 0.90
Follow-up observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. Blood (1981) 0.89
Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone. J Clin Psychiatry (2001) 0.89
Evaluation of a multi-disease carrier screening programme in Ashkenazi Jewish high schools. Clin Genet (2010) 0.89
Human hybridomas from patients with malignant disease. Br J Cancer (1983) 0.88
Specialist surgeons and survival in breast cancer. Breast cancer is a medical, not a surgical, disease. BMJ (1996) 0.88
Primary hepatocellular carcinoma localised by a radiolabelled monoclonal antibody. J Hepatol (1986) 0.87
Testicular cancer and social class in East Anglia. Br J Cancer (1984) 0.87
Oncoprotein stability after tumour resection. Br J Cancer (1990) 0.87
Gastric cancer and cimetidine: does delay in diagnosis matter? Lancet (1981) 0.87
Antenatal analysis of the human chromosomes. Am J Obstet Gynecol (1966) 0.86
Localisation of lung cancer by a radiolabelled monoclonal antibody against the c-myc oncogene product. Br J Cancer (1986) 0.85
Monoclonal antibodies in oncology. J Clin Pathol (1982) 0.84
Tumour imaging and drug targeting. Br Med Bull (1984) 0.84
The interleukin-1 receptor antagonist gene: a single-copy variant of the intron 2 variable number tandem repeat (VNTR) polymorphism. Eur J Immunogenet (2002) 0.84
RAGE-dependent regulation of calcium-binding proteins S100A8 and S100A9 in human THP-1. Exp Clin Endocrinol Diabetes (2011) 0.84
Evaluation of a Tay-Sachs disease screening program. Clin Genet (2003) 0.84
Bleomycin lung: computed tomographic observations. Br J Radiol (1985) 0.84
Oncogenes and germ cell tumours. Int J Androl (1987) 0.83
CAG repeat polymorphism in the DNA polymerase gamma gene in a Polish population: an association with testicular cancer risk. Ann Oncol (2005) 0.83
A global strategy for radiotherapy: a WHO consultation. Clin Oncol (R Coll Radiol) (1999) 0.83
The effect of ascorbic acid (vitamin C) on two tumor cell lines in culture. Oncology (1978) 0.83
An efficacy analysis of olanzapine treatment data in schizophrenia patients with catatonic signs and symptoms. J Clin Psychiatry (2001) 0.83
Human monoclonal antibodies. Nature (1982) 0.82
Cancer follow up: time for review. J R Coll Gen Pract (1985) 0.82
Serum PAF-acetylhydrolase in severe renal or hepatic disease in man: relationship to circulating levels of PAF and effects of nephrectomy or transplantation. J Lipid Mediat Cell Signal (1994) 0.82
Flow cytometric quantitation of the c-myc oncoprotein in archival neoplastic biopsies of the colon. Mol Cell Probes (1987) 0.82
Tumour localisation by human monoclonal antibodies. Med Oncol Tumor Pharmacother (1985) 0.81
Overcoming challenges of cancer treatment programmes in developing countries: a sustainable breast cancer initiative in Ethiopia. Clin Oncol (R Coll Radiol) (2008) 0.81
Inhibition of the serine/threonine protein phosphatases PP1 and PP2A in lymphocytes: effect on mRNA levels for interleukin-2, IL-2R alpha, krox-24, p53, hsc70 and cyclophilin. Immunology (1992) 0.81
Assessment of brain changes with registered MR before and after bone marrow transplantation for chronic myeloid leukemia. AJNR Am J Neuroradiol (1996) 0.81
Serum levels of Mullerian inhibiting substance in boys with cryptorchidism. J Pediatr Surg (1991) 0.80
Immunoprotection by embryonal carcinoma cells for methylcholanthrene-induced murine sarcomas. Nature (1977) 0.80
Localisation of malignant glioma by a radiolabelled human monoclonal antibody. J Neurol Neurosurg Psychiatry (1983) 0.80
Complementary and conventional cancer care: the integration of two cultures. Clin Oncol (R Coll Radiol) (1993) 0.80
c-myc oncogene expression and clinical outcome in carcinoma of the cervix. Mol Cell Probes (1989) 0.80
A novel exon within the mdm2 gene modulates translation initiation in vitro and disrupts the p53-binding domain of mdm2 protein. Oncogene (1999) 0.80
New combination chemotherapy programme for bladder cancer. Br J Urol (1989) 0.80
Human monoclonal antibodies to glioma cells. Br J Cancer (1981) 0.80
Multidrug resistance and behavioural phenotype of cancer cells. Cell Biol Int (1993) 0.80
The current management of testicular cancer. Br J Urol (1987) 0.79
Glycemic control with Humalog Mix25 in type 2 diabetes inadequately controlled with glyburide. Clin Ther (2001) 0.79
Temperature is the evil twin: effects of increased temperature and ocean acidification on reproduction in a reef fish. Ecol Appl (2015) 0.79
Hepatotrophic effect of cyclosporine and FK 506 is not mimicked by rapamycin. Transplant Proc (1999) 0.79
Proteolytic cleavage of p53 mutants in response to mismatched DNA. Br J Cancer (1999) 0.79
Evidence to support a change in follow-up policy for patients with breast cancer: time to first relapse and hazard rate analysis. Clin Oncol (R Coll Radiol) (1999) 0.79
Expression of c-myc oncogene in coeliac disease. J Clin Pathol (1987) 0.79
Suppression of foreign body granuloma by recombinant interferon. Br Med J (Clin Res Ed) (1984) 0.79
Cell-surface oligosaccharides expressed by phenotypically distinct sublines of the Dunning 3327 rat prostate cancer. Biochem Soc Trans (1990) 0.79